ASH Spotlight on CAR T-Cell Therapy
Advances in patient outcomes
Roundtable
Roundtable discussion with top experts in CAR T-cell therapy
Expert Insights
Video interviews with Experts at the ASH
Oral & Poster Sessions
Summaries of conference presentations
Podcasts
Podcast episodes in which our hosts discuss the latest CAR-T cell therapy developments
Meet the Trialist
Interviews with principle investigators of major trials
Supportive materials & tools
Coming soon
Expert Insights
Video interviews with top experts at the ASH
Diffuse Large B-Cell Lymphoma
Impact of molecular features of DLBCL on treatment outcomes with anti-CD19 CAR T-cell therapy
Interview with Dr Brian Hill, Cleveland Clinic, OH, USA
Interview with Dr Francesco Maura,
Sylvester Comprehensive Cancer Center, University of Miami, FL, USA
Lisocabtagene Maraleucel
Lisocabtgene maraleucel, a CD19 directed CAR T-cell therapy, versus standard of care in the TRANSFORM trial
Interview with Dr Manali Kamdar,
University of Colorado Cancer Center, CO, USA
ZUMA-7, BELINDA and TRANSFORM Trials
Expert Opinion of ZUMA-7, BELINDA, and TRANSFORM randomised controlled trials
Interview with Prof. Martin Dreyling,
University of Munich, Germany
Tisagenlecleucel vs Standard of Care
Tisagenlecleucel vs standard of care as second-line therapy of primary refractory or relapsed agressive B-cell non-Hodgkin lymphoma
Interview with Prof. Michael Bishop,
University of Chicago, IL, USA
Participation of Black Americans in Clinical Trials
Enrollment of Black Americans in pivotal clinical trials supporting FDA CAR T-Cell therapy approval
Interview with Dr Samer Al Hadidi,
University of Arkansas for Medical Sciences, AR, USA
Oral and Poster Presentations
Summaries of the most impactful sessions
High CR rates for novel CAR T-cell therapy in follicular lymphoma and DLBCL
Dr Jing-Zhou Hou, University of Pittsburgh Medical Center, PA, USA
ATALANTA-1: Promising data for novel CAR T-cell therapy
Prof. Marie José Kersten, Amsterdam University Medical Center, the Netherlands
ZUMA-5: Curative potential of axi-cel in follicular lymphoma
Prof. Sattva Neelapu, MD Anderson Cancer Center, TX, USA
Promising phase 1 results for novel CAR T-cell therapy in MM
Prof. Marie José Kersten, Amsterdam University Medical Center, the Netherlands
Long-term success for CD19 CAR T-cell therapy in CLL
Dr Emily Liang, University of Washington, WA, USA
ASCT or CAR T cell as first-line therapy for MM?
Prof. Salomon Manier, Lille University Hospital, France
Promising results for novel CAR-T therapy in relapsed/refractory multiple myeloma
Prof. Juan Du, Shanghai Chang Zheng Hospital, China
Axi-cel more effective but tisa-cel less toxic in DLBCL
Dr Emmanuel Bachy, Hospices Civils de Lyon, France
Second-line tisa-cel similar to standard-of-care for R/R aggressive non-Hodgkin lymphoma
Dr Michael Bishop, University of Chicago, IL, USA
CAR-Hematotox score predicts toxicity, infections, and clinical outcomes in MCL
Dr Kai Rejeski, LMU Munich, Germany
CAR-Hematotox score proves useful in relapsed/refractory MM
Dr Kai Rejeski, LMU Munich, Germany
High rate of rapid and complete responses with axi-cel in high-risk large B-cell lymphoma
Dr Sattva Neelapu, MD Anderson Cancer Center, TX, USA
Meet the Trialist
Principal investigators about their trials
Interview with Dr Sergio Giralt (Memorial Sloan Kettering Cancer Center, NY, USA) on the results of the KarMMa-3 trial
Interview with Dr Kelly Kenzik (Institute for Cancer Outcomes and Survivorship, University of Alabama, USA) on real-world outcomes after CAR T-cell therapy
CD22-directed CAR T-cell therapy safe and well-tolerated in R/R LBCL
Interview with Dr Matthew Frank (Stanford University School of Medicine, USA) on phase 1 dose-escalation results
1981
Company fouded
200+
Conferences covered
120+
Countries reached
150,000
Physicians served
This is a demo website for presentation purposes only!
The views and opinions of the interviewees and presenters are their own, and do not necessarily represent the stance or responsibility of the Editor nor the Publisher. The content is provided for informational purposes only and should not be considered official editorial content, endorsement or medical advice.
Copyright 2025: Medicom Medical Publishers BV